Pharma Pulse: Vinay Prasad Reinstated as FDA CBER Head, New COVID-19 Risk Data, and the Industry’s Response to Rising Costs

This episode of Pharma Pulse covers Vinay Prasad’s return to lead the FDA’s biologics center after a brief resignation, new research on severe COVID-19 risks for childhood cancer survivors, and the strategies pharma companies are adopting to stay competitive amid escalating healthcare costs.